Viatris Inc. (VTRS), a global pharmaceutical company, recently faced a price ceiling that has persisted for five years. The stock rose from approximately $10 in late 2024 to nearly $13.55, before encountering resistance at this long-standing barrier.
The $13.55 level has been a multi-year resistance zone, holding firm through 2020, 2021, and into 2022. Despite the recent surge, Viatris remains below this threshold, challenging patience as it tests this technical barrier.
Price reached $13.55 before dropping to $12.84, marking a decline of 2.36%, indicating exhaustion at resistance. This points to selling pressure from traders who bought at earlier highs and are now exiting.
Traders are now watching whether this decline signals consolidation before another push higher or deeper retracement. A crucial support zone lies between $12.20-$12.40, needing strength to set up a potential challenge of $13.55 once more.
Patience is key as VTRS establishes its direction either by forming a base for a breakout or confirming the recent rally was too soon. A confirmed break above $13.55 could lead to a path towards $15-$16. Until then, the persistent resistance remains unyielding.
Viatris is telling us a clear story at the $13.55 resistance level, and for options traders, this creates a defined opportunity. The stock’s powerful rally from late 2024 has stalled at a ceiling that has held firm for years, presenting a classic setup for strategies that benefit from a pause or reversal. Given this strong rejection, we should consider trades that capitalize on the stock’s failure to break higher in the immediate term.
For those of us who believe this multi-year resistance will hold for now, selling a bear call spread is a high-probability trade. One could sell the February $14 call and buy the February $15 call to limit risk, collecting a premium if VTRS stays below $14 through expiration. This strategy profits from both a pullback and sideways consolidation, reflecting the overhead supply from traders who bought near these levels back in 2021 and 2022.
The upcoming earnings report in late February adds another layer to this situation, and we are already seeing implied volatility begin to rise. The broader healthcare sector, as measured by the XLV, has been sluggish to start 2026 after a decent run last year, suggesting Viatris may lack the sector-wide momentum for a breakout. This macro backdrop supports a more cautious or neutral stance on the stock’s immediate direction.
A look at the options chain shows significant open interest building at the February $14 and $15 strike prices, confirming this level is a battleground. This indicates many traders are either betting on a breakout or, like us, selling those calls to bet against it. As of this week, data shows put option volume has been steadily increasing relative to call volume, a sign that more market participants are positioning for a potential downturn or buying protection.
If you believe the recent rally has more strength, a risk-defined bullish position is more prudent than buying the stock outright. A bull call spread, such as buying a March $13 call and selling a March $15 call, would offer upside if a breakout occurs while capping potential losses if the resistance holds firm. We need to see the stock successfully defend the $12.20 support zone on any pullback for this scenario to remain viable.
Looking back at 2025, we saw Viatris struggle to gain traction even on positive news while it was trading in the $10-$11 range. That history of price memory makes the current fight at this major resistance level even more significant. Until the stock proves it can break through with conviction and heavy volume, we should respect the ceiling that has been in place for years.
